JP7171611B2 - 網膜症を治療するための組成物及び方法 - Google Patents

網膜症を治療するための組成物及び方法 Download PDF

Info

Publication number
JP7171611B2
JP7171611B2 JP2019557486A JP2019557486A JP7171611B2 JP 7171611 B2 JP7171611 B2 JP 7171611B2 JP 2019557486 A JP2019557486 A JP 2019557486A JP 2019557486 A JP2019557486 A JP 2019557486A JP 7171611 B2 JP7171611 B2 JP 7171611B2
Authority
JP
Japan
Prior art keywords
tyrosine
methyl
composition
subject
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019557486A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020517663A5 (https=
JP2020517663A (ja
Inventor
スティーブン・ホフマン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2020517663A publication Critical patent/JP2020517663A/ja
Publication of JP2020517663A5 publication Critical patent/JP2020517663A5/ja
Application granted granted Critical
Publication of JP7171611B2 publication Critical patent/JP7171611B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
JP2019557486A 2017-04-21 2018-04-20 網膜症を治療するための組成物及び方法 Active JP7171611B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762488161P 2017-04-21 2017-04-21
US62/488,161 2017-04-21
PCT/US2018/028552 WO2018195411A1 (en) 2017-04-21 2018-04-20 Compositions and methods for treating retinopathy

Publications (3)

Publication Number Publication Date
JP2020517663A JP2020517663A (ja) 2020-06-18
JP2020517663A5 JP2020517663A5 (https=) 2021-05-06
JP7171611B2 true JP7171611B2 (ja) 2022-11-15

Family

ID=62117055

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019557486A Active JP7171611B2 (ja) 2017-04-21 2018-04-20 網膜症を治療するための組成物及び方法

Country Status (11)

Country Link
US (2) US11351136B2 (https=)
EP (1) EP3612225A1 (https=)
JP (1) JP7171611B2 (https=)
KR (1) KR20190138683A (https=)
CN (1) CN110769855A (https=)
AU (1) AU2018254556B2 (https=)
CA (1) CA3060417A1 (https=)
EA (1) EA201992515A1 (https=)
MX (1) MX2019012476A (https=)
PH (1) PH12019502380A1 (https=)
WO (1) WO2018195411A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12021552866A1 (en) 2019-05-14 2022-11-07 Tyme Inc Compositions and methods for treating cancer
US10905698B1 (en) 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003516963A (ja) 1999-11-30 2003-05-20 アルコン，インコーポレイテッド 外網膜の疾患を処置する薬剤を製造するためのβ−アドレナリン作用受容体アンタゴニストの使用
JP2004514700A (ja) 2000-11-30 2004-05-20 ファイザー・プロダクツ・インク Ｇａｂａアゴニスト及びアルドース還元酵素阻害剤の組み合わせ
JP2010516761A (ja) 2007-01-24 2010-05-20 ボーマック リサーチ リミテッド 局所処方物
US20100204325A1 (en) 2009-02-11 2010-08-12 Allergan, Inc. Valproic acid drug delivery systems and intraocular therapeutic uses thereof
JP2011508775A (ja) 2008-01-03 2011-03-17 ビオマリン プハルマセウトイカル インコーポレイテッド Ｂｈ４応答性状態を治療するためのプテリン類似体
JP2011509917A (ja) 2007-01-29 2011-03-31 ブイライフ サイエンス テクノロジーズ ピーブイティー リミテッド 糖尿病性合併症治療用薬学的組成物
US20140128460A1 (en) 2012-03-29 2014-05-08 Children's Hospital Medical Center Use of small molecule inhibitors targeting eya tyrosine phosphatase
JP2015509101A (ja) 2012-01-17 2015-03-26 タイム，インコーポレーテッド 薬学的組成物及び方法
US20150111878A1 (en) 2013-10-22 2015-04-23 Steven Hoffman Compositions and methods for treating intestinal hyperpermeability
WO2016105530A1 (en) 2014-12-23 2016-06-30 Steven Hoffman Transdermal formulations
JP2016534071A (ja) 2013-10-22 2016-11-04 タイム，インコーポレーテッド チロシン誘導体及びそれを含む組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0451422A1 (en) * 1990-04-13 1991-10-16 Merrell Dow Pharmaceuticals Inc. Pharmaceutically active fluoromethyltyrosine compounds
DE60023926T2 (de) * 1999-09-10 2006-07-20 Merck & Co., Inc. Tyrosin kinase inhibitoren
US9687528B2 (en) 2014-12-23 2017-06-27 Steven Hoffman Transdermal formulations

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003516963A (ja) 1999-11-30 2003-05-20 アルコン，インコーポレイテッド 外網膜の疾患を処置する薬剤を製造するためのβ−アドレナリン作用受容体アンタゴニストの使用
JP2004514700A (ja) 2000-11-30 2004-05-20 ファイザー・プロダクツ・インク Ｇａｂａアゴニスト及びアルドース還元酵素阻害剤の組み合わせ
JP2010516761A (ja) 2007-01-24 2010-05-20 ボーマック リサーチ リミテッド 局所処方物
JP2011509917A (ja) 2007-01-29 2011-03-31 ブイライフ サイエンス テクノロジーズ ピーブイティー リミテッド 糖尿病性合併症治療用薬学的組成物
JP2011508775A (ja) 2008-01-03 2011-03-17 ビオマリン プハルマセウトイカル インコーポレイテッド Ｂｈ４応答性状態を治療するためのプテリン類似体
US20100204325A1 (en) 2009-02-11 2010-08-12 Allergan, Inc. Valproic acid drug delivery systems and intraocular therapeutic uses thereof
JP2015509101A (ja) 2012-01-17 2015-03-26 タイム，インコーポレーテッド 薬学的組成物及び方法
US20140128460A1 (en) 2012-03-29 2014-05-08 Children's Hospital Medical Center Use of small molecule inhibitors targeting eya tyrosine phosphatase
US20150111878A1 (en) 2013-10-22 2015-04-23 Steven Hoffman Compositions and methods for treating intestinal hyperpermeability
JP2016534071A (ja) 2013-10-22 2016-11-04 タイム，インコーポレーテッド チロシン誘導体及びそれを含む組成物
JP2016538254A (ja) 2013-10-22 2016-12-08 スティーブン・ホフマン 腸透過性亢進を治療するための組成物及び方法
WO2016105530A1 (en) 2014-12-23 2016-06-30 Steven Hoffman Transdermal formulations

Also Published As

Publication number Publication date
WO2018195411A1 (en) 2018-10-25
EA201992515A1 (ru) 2020-04-09
US12364676B2 (en) 2025-07-22
EP3612225A1 (en) 2020-02-26
US20180303783A1 (en) 2018-10-25
AU2018254556A1 (en) 2019-11-14
MX2019012476A (es) 2020-02-12
PH12019502380A1 (en) 2020-09-14
US11351136B2 (en) 2022-06-07
US20220288003A1 (en) 2022-09-15
KR20190138683A (ko) 2019-12-13
CA3060417A1 (en) 2018-10-25
AU2018254556B2 (en) 2024-05-02
CN110769855A (zh) 2020-02-07
JP2020517663A (ja) 2020-06-18

Similar Documents

Publication Publication Date Title
US11786496B2 (en) Composition and methods for treating intestinal hyperpermeability
JP2021001194A (ja) 腸透過性亢進を治療するための組成物及び方法
JP2012500800A (ja) 神経因性疼痛の治療法
CN107835695A (zh) 用于治疗自闭症的组合物和方法
US20200215082A1 (en) Dihydrotestosterone and Dihydrotestosterone Derivatives and Promoters in the Treatment of Cancer
US12364676B2 (en) Compositions and methods for treating retinopathy
JPWO2020129964A1 (ja) ウルソデオキシコール酸を含有する老視の治療または予防剤
AU2017232348A1 (en) Pharmaceutical compositions for the treatment of cancer
JP6657315B2 (ja) フェノキシプロピルアミン化合物を使用してうつ病を治療する方法
US9023859B2 (en) Composition and method for treating or preventing skeletal muscle fibrosis
EA046053B1 (ru) Композиции и способы для лечения ретинопатии
WO2016085981A1 (en) Method of inhibiting or treating fibrosis
US20250170143A1 (en) Methods of treating ocular fibrotic pathologies
OA21243A (en) Compounds for treatment of alzheimer's disease.
AU2016216637A1 (en) Composition and method for treating or preventing skeletal muscle fibrosis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210316

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210316

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211213

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211217

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220315

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220322

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220328

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220628

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221004

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221102

R150 Certificate of patent or registration of utility model

Ref document number: 7171611

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250